Clinical Trial Search

Primary: Percentage of Patients With HER2- Primary Breast Cancer Who Develop Imagable HER2+ Metastases — 13 % of participants

Primary: Brief Pain Inventory (BPI)- Short Form (SF) Question 3 (BPI-SF3) — 5.6; 6; 5.67; 6.5 score on a scale

Primary: Number of Participants Who Experienced an Adverse Event (AE) — 6; 6; 6; 6 Participants

Primary: Disease Control Rate — 34.5; 36.6; 25.6 Percentage of participants

Primary: Effectiveness of SCS Stimulation in Reducing Back Pain Associated With Failed Back Surgery Syndrome After 12 Months of Use.

Primary: Evaluation of Spontaneous Pain Scores — 53.52; 49.13; 41.41; 46.17 score on a scale — p=0.246

Primary: Number of Participants With Any Serious Adverse Events (SAEs) and Any Non-serious Adverse Events (Non-SAEs) — 5; 0 Participants

Primary: The Percentage of Patients in Each Treatment Group Who Experience Post-dose Increases in Liver Enzyme Levels That Are Considered a Safety Concern. — 0; 0; 0; 0…

Primary: Best Response Rate — 1; 3; 4; 4 Participants

Primary: % of Participants Who Had Smoked Cigarette(s) in the Past 7 Days (at 6 Months From Baseline) — 27; 13 % of participants

Primary: HF Hospitalizations and CV Death — 293; 372; 274; 363 Events — p=0.059

Primary: Change in Mammographic Breast Density At Study Exit — -1.85; -2.14; -3.75 percent change from baseline

Primary: Cerebral Blood Flow and VAS With Optimal Paresthesia Coverage Compared With SCS Off

Primary: Maximum Tolerated Dose (MTD) of Lenalidomide and CHOEP — 10 milligrams

Primary: Number of Subjects With Any Solicited General Adverse Events (AEs) After the First Vaccination — 139; 166; 41; 47 Participants